Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851918 | 0.88 | NPSR1 (0.35) | NPSR1CYP4F2CYP4A11LMNAOPRM1 | |
| Hydrochloric Acid SCHEMBL19281613 | 0.86 | NPSR1 (0.34) | NPSR1LMNAOPRM1 | |
| SCHEMBL2077252 | 0.85 | NPSR1 (0.37) | NPSR1CYP4F2CYP4A11LMNAOPRM1 | |
| Hydrochloric Acid SCHEMBL2077250 | 0.83 | NPSR1 (0.36) | NPSR1CYP4F2CYP4A11OPRM1 | |
| SCHEMBL28736620 | 0.80 | OPRM1 (0.41) | ALDH1A1LMNAOPRM1 | |
| SCHEMBL1603102 | 0.79 | — | — | |
| SCHEMBL15198721 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL21296019 | 0.77 | NPSR1 (0.34) | NPSR1LMNA | |
| SCHEMBL17892425 | 0.77 | NPSR1 (0.37) | NPSR1ALDH1A1CYP4F2CYP4A11LMNA | |
| SCHEMBL30936120 | 0.77 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | claimed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
| CN-101511354-A | Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseases | AICURIS GMBH & CO KG (DE) | 2009-08-19 | — | — | CN | disclosed |
| WO-2008022725-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISORDERS | AICURIS GMBH & CO. KG (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | DHFR, RORA, CYP2A6 | NPSR1 1530/4885ALDH1A1 123/4885CYP4F2 406/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | NPSR1 399/4885ALDH1A1 4236/4885CYP4F2 2014/4885 |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | METAP2, METAP1, LNPEP | NPSR1 881/4885ALDH1A1 3706/4885CYP4F2 1324/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | NPSR1 257/4885ALDH1A1 2398/4885CYP4F2 1112/4885 |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | NPSR1 206/4885ALDH1A1 2646/4885CYP4F2 2014/4885 |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | NPSR1 257/4885ALDH1A1 2398/4885CYP4F2 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.